TRT and elevated hematocrit: what the evidence actually shows

What's this video probably claiming?

Based on the caption and creator context, Dr. David Hall is likely arguing that elevated hematocrit in TRT patients is not always caused by testosterone itself, and that other contributing factors are being overlooked by clinicians. This is a reasonable clinical point that gets made in endocrinology circles, but it also has a way of sliding into minimization territory on social media. The argument typically goes something like this: sleep apnea, dehydration, altitude, and primary polycythemia can all raise hematocrit independently of testosterone, so providers shouldn't be too quick to reduce a patient's dose or pull them off TRT entirely. That framing is partially defensible. However, the degree to which TRT is downplayed as a driver varies wildly depending on who's making the argument and why. A TRT-adjacent creator with fitness and lifestyle hashtags warrants a closer look at whether the nuance holds up.

What does the science actually show?

Testosterone absolutely raises hematocrit. This is not a fringe finding. A 2010 meta-analysis by Calof et al. in the Journals of Gerontology found that men on testosterone therapy had a significantly higher risk of polycythemia compared to placebo. Fernandez-Balsells et al. (2010, Annals of Internal Medicine) confirmed elevated hematocrit as one of the most consistent adverse effects across TRT trials. The mechanism is well-established: testosterone stimulates erythropoietin production in the kidneys, which drives red blood cell production. Studies using testosterone cypionate at doses of 100-200mg per week report hematocrit increases of 3-7 percentage points on average, with some men exceeding the 54% threshold considered clinically significant. It is also true, however, that obstructive sleep apnea is an independent driver of erythrocytosis, and a 2016 paper by Morales et al. in the Canadian Urological Association Journal specifically flagged the overlap between sleep apnea prevalence and TRT populations. So yes, other causes exist. But testosterone remains the primary variable to interrogate first.

Where does the social media noise diverge from clinical reality?

The problem with this category of TRT content is not that the individual claims are false. It's that the framing tends to serve a specific audience, which is men who want to stay on their current testosterone dose and would prefer a narrative that says the hematocrit issue is being overcomplicated by cautious doctors. The Endocrine Society guidelines recommend checking hematocrit at baseline, 3-6 months after starting therapy, and annually thereafter, with dose reduction or therapeutic phlebotomy if levels exceed 54%. That threshold exists for a reason. Elevated hematocrit increases blood viscosity, which raises theoretical thrombotic risk, though the direct cardiovascular evidence remains debated. Coviello et al. (2008, Journal of Clinical Endocrinology and Metabolism) showed dose-dependent hematocrit increases in healthy men, which matters when social media content implies that standard clinical TRT doses are essentially benign for erythrocytosis. Nuance is not the same as reassurance.

What should you actually know?

If you are on TRT and your hematocrit is elevated, the right response is not to immediately assume it's something other than testosterone. Start there. A thorough workup should rule out secondary causes including sleep apnea, which is genuinely common and genuinely underdiagnosed in men seeking TRT, chronic hypoxia, and primary polycythemia vera. A JAK2 mutation test is appropriate if polycythemia vera is suspected. But if workup is negative and you're on testosterone, the testosterone is probably contributing. Dose adjustments, route changes (gels tend to cause less erythrocytosis than injections), or therapeutic phlebotomy are the standard management options depending on severity. The Endocrine Society and American Urological Association both treat hematocrit above 54% as a reason to pause or modify therapy, not as a data point to contextualize away. Any provider or content creator suggesting otherwise should be asked to show their work, and their financial relationships with TRT clinics.